Abstract:We aimed to investigate the diagnostic and prognostic value of 68Ga-pentixafor PET/CT imaging in noncancer patients with suspected adrenal masses. Methods: Sixty-four patients who had benign adrenal masses on CT were retrospectively included in our study. All patients underwent 68Ga-pentixafor PET/CT, and 56 of these patients subsequently underwent adrenalectomy. The subtypes of 81 adrenal tumors, including 14 nonfunctioning adrenal nodules, 4 cortisol-producing adenomas, 41 aldosterone-producing adenomas, 5 cases of suspected unilateral adrenal hyperplasia, 15 cases of idiopathic aldosterone hyperplasia, and 2 pheochromocytomas, were determined by histology or follow-up evaluations. The diagnostic efficiency of functional lateralization was calculated by visual analysis. Semiquantitative parameters of these lesions, including SUVmax, the ratio of lesional SUVmax to normal liver SUVmean (LLR), and the ratio of lesional SUVmax to contralateral adrenal tissue SUVmean (LCR), were also calculated. Dynamic analysis was also performed on 15 patients. In addition, clinical outcomes were assessed and compared in patients who underwent adrenalectomy. Results: The sensitivity and specificity of 68Ga-pentixafor PET for functional lateralization in patients with adrenocortical lesions were 97.8% (45/46) and 87.5% (14/16), respectively. The 2 pheochromocytoma lesions had lower pentixafor uptake than the normal adrenal glands. Functioning (active) adrenocortical adenomas showed an elevated SUVmax of 16.3 ± 7.9, in comparison to 4.4 ± 1.7 in nonfunctioning (inactive) adenomas and 5.5 ± 2.7 in hyperplasia lesions (P < 0.0001). To identify active adrenocortical adenomas, a cutoff of 7.1 for SUVmax showed a sensitivity of 90.9% and a specificity of 85.3% (area under receiver-operating-characteristic curve, 0.96; P < 0.0001); a cutoff of 2.5 for LLR showed a sensitivity of 95.5% and a specificity of 88.2% (area under receiver-operating-characteristic curve, 0.97; P < 0.0001); and a cutoff of 2.4 for LCR showed a sensitivity of 88.6% and a specificity of 91.8% (area under receiver-operating-characteristic curve, 0.95; P < 0.0001). The graphical influx rate constant of active adrenocortical adenomas was significantly higher than that of inactive adenomas. Uptake values for 68Ga-pentixafor were significantly higher in patients with preferable outcomes (cured/improved) (SUVmax, 15.5 ± 8.0; LLR, 6.5 ± 4.3; LCR, 6.2 ± 5.0) than in patients with nonpreferable outcomes (no improvement) (SUVmax, 4.2 ± 0.5; LLR, 1.3 ± 0.2; LCR, 1.5 ± 0.6; all P < 0.0001). Conclusion:68Ga-pentixafor PET/CT imaging exhibits great potential for noninvasive functional lateralization and characterization in patients with adrenocortical masses.

18F-FDG PET Imaging for Differentiating Malignant from Benign Lesions in Patients with Adrenal Masses

[FDG-PET in the Diagnosis of Pulmonary Lesions].

Diagnostic Value of 18F-FDG PET/CT in Differentiating the Cardiac Benign from Malignant Lesions

Evaluation of lung lesions using FDG γ-camera PET equipped with a one-inch crystal

Clinical Application of 18F-FDG PET/CT in Diagnosis of Cardiac Neoplasm

Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68Ga-Pentixafor.

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Diagnosis of Benign Pulmonary Lesions in Sarcoidosis

Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands

The Preliminary Application of ~(18)F-FDG PET in Detecting Malignant Tumors

Diagnosis Ability of Dual-Phase F-18-fluoro-2-deoxy-D-glucose SPECT/PET for Distinguishing the Benign and Malignant Lesions

[18F]FDG-PET/CT in adrenal lesions: diagnostic performance in different clinical settings

Application of FDG-PET for Detection of Malignant Lesions in Patients with Elevated Blood Tumor Markers but Without a History of Malignancy

~(18)FDG-SPECT with coincidence in detection of lung lesions

Role of 18F-FDG PET/CT Imaging in Cardiac Masses

Application of 18F-FDG PET/CT in Diagnosis and Management of Renal Tumors

The diagnostic value of Na~(18)F PET/CT imaging in bone metastasis

The Diagnosis of 18 F-fluorodexoxyglucose and 11C-Acetate PET/CT Scanning in Primary Liver Tumors and Tumor-Like Diseases : a Preliminary Study

Retrospective analysis of 116 patients and diagnostic value of 18F-FDG PET/CT in hepatic tumor

Comparison Between ~(18)F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography(pet/ct) and Conventional Imagings in Detection of the Primary Tumor of Patients with Bone Metastasis

Utility of 18F-DG PET in Diagnosis and Staging of Lymphoma

Dual Time Point 18 F-FDG PET Imaging for Differentiating Malignant from Benign Lung Nodules